FDA introduces new safety measures for extended-release and long-acting opioid medications

by FDA on July 9, 2012

in FDA Alerts

The U.S. Food and Drug Administration today approved a risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioids, highly potent drugs approved for moderate to severe, persistent pain that requires treatment for an extended period.

This is a summary of a Press Release issued by the Food and Drug Administration (FDA). The link below will take you to the original press release containing complete information, including instructions about what to do if you are affected.

View Full Details Of Original FDA Press Release Here.

Leave a Comment

Previous post:

Next post: